E-submission
Search
- Page Path
- HOME > Search
Letter to the Editor
- Response to Comment on “Prognostic Role of Claudin-1 Immunohistochemistry in Malignant Solid Tumors: A Meta-Analysis”
- Jung-Soo Pyo, Nae Yu Kim, Won Jin Cho
- J Pathol Transl Med. 2019;53(6):412-414. Published online November 1, 2019
- DOI: https://doi.org/10.4132/jptm.2019.09.27
- 3,711 View
- 60 Download
Original Articles
- Prognostic Role of Claudin-1 Immunohistochemistry in Malignant Solid Tumors: A Meta-Analysis
- Jung-Soo Pyo, Nae Yu Kim, Won Jin Cho
- J Pathol Transl Med. 2019;53(3):173-179. Published online March 5, 2019
- DOI: https://doi.org/10.4132/jptm.2019.02.03
- 5,944 View
- 158 Download
- 5 Web of Science
- 4 Crossref
-
Abstract
PDF - Background
Although the correlation between low claudin-1 expression and worse prognosis has been reported, details on the prognostic implications of claudin-1 expression in various malignant tumors remain unclear. The present study aimed to elucidate the prognostic roles of claudin- 1 immunohistochemistry (IHC) in various malignant tumors through a meta-analysis.
Methods
The study included 2,792 patients from 22 eligible studies for assessment of the correlation between claudin-1 expression and survival rate in various malignant tumors. A subgroup analysis based on the specific tumor and evaluation criteria of claudin-1 IHC was conducted.
Results
Low claudin-1 expression was significantly correlated with worse overall survival (OS) (hazard ratio [HR], 1.851; 95% confidence interval [CI], 1.506 to 2.274) and disease-free survival (DFS) (HR, 2.028; 95% CI, 1.313 to 3.134) compared to high claudin-1 expression. Breast, colorectal, esophageal, gallbladder, head and neck, and lung cancers, but not cervical, liver or stomach cancers, were significantly correlated with worse OS. Breast, colorectal, esophageal, and thyroid cancers with low claudin-1 expression were associated with poorer DFS. In the lower cut-off subgroup (< 25.0%) with respect to claudin-1 IHC, low claudin-1 expression was significantly correlated with worse OS and DFS.
Conclusions
Taken together, low claudin-1 IHC expression is significantly correlated with worse survival in various malignant tumors. More detailed criteria for claudin-1 IHC expression in various malignant tumors are needed for application in daily practice. -
Citations
Citations to this article as recorded by
- The Significance of Relative Claudin Expression in Odontogenic Tumors
Ekarat Phattarataratip, Kraisorn Sappayatosok
Head and Neck Pathology.2020; 14(2): 480. CrossRef - Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer
Simon Kind, Franziska Büscheck, Doris Höflmayer, Claudia Hube-Magg, Martina Kluth, Maria Christina Tsourlakis, Stefan Steurer, Till S. Clauditz, Andreas M. Luebke, Eike Burandt, Waldemar Wilczak, Andrea Hinsch, David Dum, Sören Weidemann, Christoph Fraune
World Journal of Urology.2020; 38(9): 2185. CrossRef - Characterisation of endogenous Claudin‐1 expression, motility and susceptibility to hepatitis C virus in CRISPR knock‐in cells
Camille M.H. Clément, Maika S. Deffieu, Cristina M. Dorobantu, Thomas F. Baumert, Nilda Vanesa Ayala‐Nunez, Yves Mély, Philippe Ronde, Raphael Gaudin
Biology of the Cell.2020; 112(5): 140. CrossRef - Comment on “Prognostic Role of Claudin-1 Immunohistochemistry in Malignant Solid Tumors: A Meta-Analysis”
Bolin Wang, Yan Huang
Journal of Pathology and Translational Medicine.2019; 53(6): 411. CrossRef
- The Significance of Relative Claudin Expression in Odontogenic Tumors
- Expression of CD43 in Colorectal Adenocarcinom.
- Kyeong Cheon Jung, Youngmee Bae, Hyekyung Ahn, Hye Eun Kim, Myung Chul Jang, Hye Rin Roh, Gi Bong Chae, Won Jin Choi, Woo Jin Kim, Weon Seo Park
- Korean J Pathol. 2004;38(1):8-14.
- 1,949 View
- 23 Download
-
Abstract
PDF
- BACKGROUND
CD43 is a sialoglycoprotein that is highly expressed on most leukocytes, except on B lymphocytes and dendritic cells. CD43 has been reported to be involved in the adhesion and apoptosis of lymphocytes. Although the aberrant expression of CD43 antigen in non-lymphoid tissues has been reported, the expression of the CD43 antigen in gastrointestinal malignancies is not well studied. Here, we studied the expression of CD43 in colon adenocarcinoma using the anti-CD43 monoclonal antibody developed in our laboratory.
METHODS
Thirty patients who had undergone surgical resection for colorectal carcinoma were recruited. The expression of CD43 molecule was determined by analyzing the formalin-fixed, paraffin-embedded specimens immunohistochemically using our newly developed anti-CD43 mAb (K06). The results obtained by the immunohistochemical analysis correlated to the clinicopatho-logical parameters.
RESULTS
The expression of CD43 were found in 20 out of 30 colorectal carcinoma cases. The expression of CD43 antigen is higher in well differentiated adenocarcinomas than poorly or moderately differentiated adenocarcinomas.
CONCLUSIONS
The new anti-CD43 mAb might be helpful for the detection of the expression of CD43 on colorectal carcinoma cells. Further studies are required to assess the relationship between the CD43 expression and the colorectal carcinogenesis.
First
Prev
